Compare Ascendis Pharma A/S (ASND) vs EPR Properties (EPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs EPR Properties — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while EPR Properties trades at $60 (market cap $4.56B). The key difference: Ascendis Pharma A/S is far larger — about 3.9× EPR Properties's market cap, and EPR Properties pays a 6.24% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EPR | |
|---|---|---|
Market Cap | $17.74B | $4.56B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $61.21 |
52-Week Low | $163.32 | $48.71 |
Enterprise Value | $18.11B | $7.62B |
Dividend Yield | — | 6.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EPR Properties trades at $59.62, up 0.08% on the day, with a bullish technical signal from moving averages. The REIT shows strong profitability with a 39.93% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $315 million Six Flags acquisition and monthly dividends, reinforcing its experiential real estate focus.
Outlook remains positive with a consensus price target of $63.00, though risks include portfolio transition execution and sensitivity to consumer discretionary spending. The stock offers a 6%+ yield with solid coverage, appealing for income investors amid stable occupancy and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
